Prognostic implications of tumor-infiltrating T cells in early-stage endometrial cancer.
Journal
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
ISSN: 1530-0285
Titre abrégé: Mod Pathol
Pays: United States
ID NLM: 8806605
Informations de publication
Date de publication:
02 2022
02 2022
Historique:
received:
02
07
2021
accepted:
08
09
2021
revised:
31
08
2021
pubmed:
14
10
2021
medline:
5
4
2022
entrez:
13
10
2021
Statut:
ppublish
Résumé
Patients with endometrial cancer differ in terms of the extent of T-cell infiltration; however, the association between T-cell subpopulations and patient outcomes remains unexplored. We characterized 285 early-stage endometrial carcinoma samples for T-cell infiltrates in a tissue microarray format using multiplex fluorescent immunohistochemistry. The proportion of T cells and their subpopulations were associated with clinicopathological features and relapse-free survival outcomes. CD3+ CD4+ infiltrates were more abundant in the patients with higher grade or non-endometrioid histology. Cytotoxic T cells (CD25+, PD-1+, and PD-L1+) were strongly associated with longer relapse-free survival. Moreover, CD3+ PD-1+ stromal cells were independent of other immune T-cell populations and clinicopathological factors in predicting relapses. Patients with high stromal T-cell fraction of CD3+ PD-1+ cells were associated with a 5-year relapse-free survival rate of 93.7% compared to 79.0% in patients with low CD3+ PD-1+ fraction. Moreover, in patients classically linked to a favorable outcome (such as endometrioid subtype and low-grade tumors), the stromal CD3+ PD-1+ T-cell fraction remained prognostically significant. This study supports that T-cell infiltrates play a significant prognostic role in early-stage endometrial carcinoma. Specifically, CD3+ PD-1+ stromal cells emerge as a promising novel prognostic biomarker.
Identifiants
pubmed: 34642425
doi: 10.1038/s41379-021-00930-7
pii: S0893-3952(22)00337-4
doi:
Substances chimiques
B7-H1 Antigen
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
256-265Informations de copyright
© 2021. The Author(s), under exclusive licence to United States & Canadian Academy of Pathology.
Références
Braun, M. M., Overbeek-Wager, E. A. & Grumbo, R. J. Diagnosis and management of endometrial cancer. Am. Fam. Physician 93, 468–474 (2016).
pubmed: 26977831
Colombo, N. et al. ESMO-ESGO-ESTRO consensus conference on endometrial cancer: diagnosis, treatment and follow-up. Ann. Oncol. 27, 16–41 (2016).
doi: 10.1093/annonc/mdv484
pubmed: 26634381
Concin, N. et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int. J. Gynecol. Cancer 31, 12–39 (2021).
doi: 10.1136/ijgc-2020-002230
pubmed: 33397713
Cree, I. A., White, V. A., Indave, B. I. & Lokuhetty, D. Revising the WHO classification: female genital tract tumours. Histopathology 76, 151–156 (2020).
doi: 10.1111/his.13977
pubmed: 31846528
Cancer Genome Atlas Research, N. et al. Integrated genomic characterization of endometrial carcinoma. Nature 497, 67–73 (2013).
doi: 10.1038/nature12113
Kommoss, S. et al. Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series. Ann. Oncol. 29, 1180–1188 (2018).
doi: 10.1093/annonc/mdy058
pubmed: 29432521
Talhouk, A. et al. Confirmation of ProMisE: a simple, genomics-based clinical classifier for endometrial cancer. Cancer 123, 802–813 (2017).
doi: 10.1002/cncr.30496
pubmed: 28061006
Liu, Y. et al. Clinical significance of CTNNB1 mutation and Wnt pathway activation in endometrioid endometrial carcinoma. J. Natl Cancer Inst. 106, dju245 (2014).
Kommoss, F. K. et al. L1CAM further stratifies endometrial carcinoma patients with no specific molecular risk profile. Br. J. Cancer 119, 480–486 (2018).
doi: 10.1038/s41416-018-0187-6
pubmed: 30050154
pmcid: 6134076
Talhouk, A. et al. Molecular subtype not immune response drives outcomes in endometrial carcinoma. Clin. Cancer Res. 25, 2537–2548 (2019).
doi: 10.1158/1078-0432.CCR-18-3241
pubmed: 30523022
Kondratiev, S., Sabo, E., Yakirevich, E., Lavie, O. & Resnick, M. B. Intratumoral CD8+ T lymphocytes as a prognostic factor of survival in endometrial carcinoma. Clin. Cancer Res. 10, 4450–4456 (2004).
doi: 10.1158/1078-0432.CCR-0732-3
pubmed: 15240536
Versluis, M. A. et al. Prediction model for regional or distant recurrence in endometrial cancer based on classical pathological and immunological parameters. Br. J. Cancer 113, 786–793 (2015).
doi: 10.1038/bjc.2015.268
pubmed: 26217922
pmcid: 4559831
de Jong, R. A. et al. Presence of tumor-infiltrating lymphocytes is an independent prognostic factor in type I and II endometrial cancer. Gynecol. Oncol. 114, 105–110 (2009).
doi: 10.1016/j.ygyno.2009.03.022
pubmed: 19411095
Piulats, J. M. et al. Molecular approaches for classifying endometrial carcinoma. Gynecol. Oncol. 145, 200–207 (2017).
doi: 10.1016/j.ygyno.2016.12.015
pubmed: 28040204
Eggink, F. A. et al. Immunological profiling of molecularly classified high-risk endometrial cancers identifies POLE-mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition. Oncoimmunology 6, e1264565 (2017).
doi: 10.1080/2162402X.2016.1264565
pubmed: 28344870
Samstein, R. M. et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat. Genet. 51, 202–206 (2019).
doi: 10.1038/s41588-018-0312-8
pubmed: 30643254
pmcid: 6365097
Guo, F., Dong, Y., Tan, Q., Kong, J. & Yu, B. Tissue infiltrating immune cells as prognostic biomarkers in endometrial cancer: a meta-analysis. Dis. Markers 1805764 (2020).
Blom, S. et al. Systems pathology by multiplexed immunohistochemistry and whole-slide digital image analysis. Sci. Rep. 7, 15580 (2017).
doi: 10.1038/s41598-017-15798-4
pubmed: 29138507
pmcid: 5686230
Pollari, M. et al. Adverse prognostic impact of regulatory T-cells in testicular diffuse large B-cell lymphoma. Eur. J. Haematol. 105, 712–721 (2020).
doi: 10.1111/ejh.13484
pubmed: 32632935
Ruz-Caracuel, I. et al. Myoinvasive pattern as a prognostic marker in low-grade, early-stage endometrioid endometrial carcinoma. Cancers (Basel) 11, 1845 (2019).
Autio, M. et al. Immune cell constitution in the tumor microenvironment predicts the outcome in diffuse large B-cell lymphoma. Haematologica 106, 718–729 (2021).
doi: 10.3324/haematol.2019.243626
pubmed: 32079690
Blom, S. et al. Fibroblast as a critical stromal cell type determining prognosis in prostate cancer. Prostate 79, 1505–1513 (2019).
doi: 10.1002/pros.23867
pubmed: 31269283
pmcid: 6813917
Workel, H. H. et al. CD103 defines intraepithelial CD8+ PD1+ tumour-infiltrating lymphocytes of prognostic significance in endometrial adenocarcinoma. Eur. J. Cancer 60, 1–11 (2016).
doi: 10.1016/j.ejca.2016.02.026
pubmed: 27038842
Jung, I. K. et al. Tumor-infiltration of T-lymphocytes is inversely correlated with clinicopathologic factors in endometrial adenocarcinoma. Obstet. Gynecol. Sci. 57, 266–273 (2014).
doi: 10.5468/ogs.2014.57.4.266
pubmed: 25105099
pmcid: 4124087
Yamagami, W. et al. Immunofluorescence-detected infiltration of CD4+FOXP3+ regulatory T cells is relevant to the prognosis of patients with endometrial cancer. Int. J. Gynecol. Cancer 21, 1628–1634 (2011).
doi: 10.1097/IGC.0b013e31822c271f
pubmed: 21897268
Sungu, N. et al. Expression of immunomodulatory molecules PD-1, PD-L1, and PD-L2, and their relationship with clinicopathologic characteristics in endometrial cancer. Int. J. Gynecol. Pathol. 38, 404–413 (2019).
doi: 10.1097/PGP.0000000000000543
pubmed: 30134343
Pasanen, A. et al. PD-L1 expression in endometrial carcinoma cells and intratumoral immune cells: differences across histologic and TCGA-based molecular subgroups. Am. J. Surg. Pathol. 44, 174–181 (2020).
doi: 10.1097/PAS.0000000000001395
pubmed: 31651527
Mo, Z. et al. Expression of PD-1, PD-L1 and PD-L2 is associated with differentiation status and histological type of endometrial cancer. Oncol. Lett. 12, 944–950 (2016).
doi: 10.3892/ol.2016.4744
pubmed: 27446374
pmcid: 4950473
Li, Z. et al. Programmed death ligand 1 expression among 700 consecutive endometrial cancers: strong association with mismatch repair protein deficiency. Int. J. Gynecol. Cancer 28, 59–68 (2018).
doi: 10.1097/IGC.0000000000001120
pubmed: 29053481
Xi, Z. et al. Evaluation of PTEN and CD4+FOXP3+ T cell expressions as diagnostic and predictive factors in endometrial cancer: A case control study. Med. (Baltim) 98, e16345 (2019).
doi: 10.1097/MD.0000000000016345
Engerud, H. et al. High degree of heterogeneity of PD-L1 and PD-1 from primary to metastatic endometrial cancer. Gynecol. Oncol. 157, 260–267 (2020).
doi: 10.1016/j.ygyno.2020.01.020
pubmed: 31973911
Pages, F. et al. Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene 29, 1093–1102 (2010).
doi: 10.1038/onc.2009.416
pubmed: 19946335
Barnes, T. A. & Amir, E. HYPE or HOPE: the prognostic value of infiltrating immune cells in cancer. Br. J. Cancer 118, e5 (2018).
doi: 10.1038/bjc.2017.417
pubmed: 29315291
pmcid: 5785752
Horeweg, N. et al. Prognostic integrated image-based immune and molecular profiling in early-stage endometrial cancer. Cancer Immunol. Res. 8, 1508–19 (2020).
doi: 10.1158/2326-6066.CIR-20-0149
pubmed: 32999003
Stelloo, E. et al. Improved risk assessment by integrating molecular and clinicopathological factors in early-stage endometrial cancer-combined analysis of the PORTEC cohorts. Clin. Cancer Res. 22, 4215–4224 (2016).
doi: 10.1158/1078-0432.CCR-15-2878
pubmed: 27006490